Clinical Trials Logo
  1. Home
  2. Pancreatic Neuroendocrine Tumor
  3. NCT03074513

Atezolizumab and Bevacizumab in Treating Patients With Rare Solid Tumors

Neuroendocrine Carcinoma Clinical Trial

Official title:
A Phase II, Single-Arm Open-Label Study of the Combination of Atezolizumab and Bevacizumab in Rare Solid Tumors

Clinical Trial Summary

This phase II trial studies how well atezolizumab and bevacizumab work in treating patients with rare solid tumors. Immunotherapy with monoclonal antibodies, such as atezolizumab and bevacizumab, may help the body's immune system attack the cancer, and may interfere with the ability of tumor cells to grow and spread.

Clinical Trial Description

PRIMARY OBJECTIVES: I. To evaluate the efficacy of atezolizumab when given in combination with bevacizumab (atezo bev). SECONDARY OBJECTIVES: I. To evaluate the efficacy of atezo bev. II. To evaluate the safety of atezo + bev. EXPLORATORY BIOMARKER OBJECTIVES: I. To identify biomarkers that are predictive of response to atezo bev (i.e., predictive biomarkers), are associated with progression to a more severe disease state (i.e., prognostic biomarkers), are associated with resistance to atezo bev, are associated with susceptibility to developing adverse events, can provide evidence of study treatment activity, or can increase the knowledge and understanding of disease biology. OUTLINE: Patients receive atezolizumab and bevacizumab intravenously (IV) over 60 minutes on day 1. Courses repeat every 21 days in the absence of disease progression or unacceptable toxicity. After completion of study treatment, patients are followed up every 3 months. ;

Study Design

Related Conditions & MeSH terms

  • Appendix Adenocarcinoma
  • Carcinoma
  • Carcinoma, Merkel Cell
  • Carcinoma, Neuroendocrine
  • Carcinoma, Squamous Cell
  • Human Papillomavirus-Related Anal Squamous Cell Carcinoma
  • Human Papillomavirus-Related Cervical Squamous Cell Carcinoma
  • Human Papillomavirus-Related Squamous Cell Carcinoma of the Penis
  • Human Papillomavirus-Related Vulvar Squamous Cell Carcinoma
  • Lung Neoplasms
  • Mesothelioma
  • Mesothelioma, Malignant
  • Nasopharyngeal Carcinoma
  • Neuroendocrine Carcinoma
  • Neuroendocrine Tumors
  • Pancreatic Neuroendocrine Tumor
  • Recurrence
  • Recurrent Merkel Cell Carcinoma
  • Recurrent Nasopharynx Carcinoma
  • Recurrent Peritoneal Malignant Mesothelioma
  • Recurrent Pleural Malignant Mesothelioma
  • Stage III Merkel Cell Carcinoma AJCC v7
  • Stage III Nasopharyngeal Carcinoma AJCC v7
  • Stage III Pleural Malignant Mesothelioma AJCC v7
  • Stage IV Merkel Cell Carcinoma AJCC v7
  • Stage IV Nasopharyngeal Carcinoma AJCC v7
  • Stage IV Pleural Malignant Mesothelioma AJCC v7
  • Stage IVA Nasopharyngeal Carcinoma AJCC v7
  • Stage IVB Nasopharyngeal Carcinoma AJCC v7
  • Stage IVC Nasopharyngeal Carcinoma AJCC v7
  • Vaginal Squamous Cell Carcinoma, Not Otherwise Specified
Clinical Trial Details
NCT number NCT03074513
Study type Interventional
Source M.D. Anderson Cancer Center
Contact
Status Active, not recruiting
Phase Phase 2
Start date March 3, 2017
Completion date September 30, 2025
View Details
See also
  Status Clinical Trial Phase
Completed NCT01642251 - Cisplatin and Etoposide With or Without Veliparib in Treating Patients With Extensive Stage Small Cell Lung Cancer Phase 1/Phase 2
Recruiting NCT04069299 - Use of 68Ga-dotatate PET Scan in Neuroendocrine Carcinoma of the GI Tract
Recruiting NCT04464122 - Rediscovering Biomarkers for the Diagnosis and Early Treatment Response in NEN (REBORN)
Recruiting NCT04325425 - Chemotherapy For Metastatic Grade 3 Poorly Differentiated NEuroendocrine Carcinoma Of GastroEnteroPancreatic And Unknown Primary Phase 2
Completed NCT03834701 - Endoscopic Ultrasound-guided RadioFrequency Ablation for the Treatment Pancreatic NeuroEndocrine Neoplasms N/A
Recruiting NCT03279614 - Study to Evaluate the Efficiency of SOX as Seconde-line Chemotherapy in Neuroendocrine Carcinoma Phase 2
Recruiting NCT05978284 - Study of ZG006 in Participants With Small Cell Lung Cancer or Neuroendocrine Carcinoma Phase 1/Phase 2
Recruiting NCT05076786 - Chidamide Plus Etoposide and Cisplatin/Carboplatin as First-line Treatment for Extrapulmonary Neuroendocrine Carcinoma Phase 2
Completed NCT00388063 - Safety and Efficacy of Atiprimod Treatment for Patients With Low to Intermediate Grade Neuroendocrine Carcinoma Phase 2
Withdrawn NCT03901378 - Pembrolizumab With Chemotherapy in Metastatic or Unresectable High Grade Gastroenteropancreatic or Lung Neuroendocrine Carcinoma Phase 2
Recruiting NCT02970786 - Phase I Trial: 68Ga-NODAGA-E(c[RGDyK])2 Positron Emission Tomography for Imaging Angiogenesis in Primary and Metastatic Tumor Lesions in Humans Phase 1
Completed NCT00663429 - Extension Study of the Safety and Efficacy of Atiprimod Treatment in Neuroendocrine Carcinoma Phase 2
Recruiting NCT05113355 - Chidamide Plus Sintilimab for Chemotherapy-refractory Advanced High-grade Neuroendocrine Neoplasm Phase 2
Completed NCT03278405 - Avelumab in G3 NEC Phase 1/Phase 2
Active, not recruiting NCT03837977 - Second-line Therapy for Patients With Progressive Poorly Differentiated Extra-pulmonary Neuroendocrine Carcinoma Phase 2
Recruiting NCT06372626 - Study of ZG005 in Combination With Etoposide and Cisplatin in Participants With Advanced Neuroendocrine Carcinoma. Phase 1/Phase 2
Not yet recruiting NCT06333314 - Dostarlimab for Locally Advanced or Metastatic Cancer (Non-colorectal/Non-endometrial) With Tumor dMMR/MSI Phase 2
Active, not recruiting NCT02687958 - Study of Everolimus as Maintenance Therapy for Metastatic NEC With Pulmonary or Gastroenteropancreatic Origin Phase 2
Completed NCT01121939 - Combination of Bevacizumab, Pertuzumab, and Sandostatin for Adv. Neuroendocrine Cancers Phase 2
Recruiting NCT03168607 - Study to Evaluate the Efficiency of FOLFIRI as Seconde-line Chemotherapy in Neuroendocrine Carcinoma Phase 2